Evidence map›Paper›PMID 38490920›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2024

Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis.

Shijing Jia, Yizhuo Wang, Melissa H Ross, Jonathan B Zuckerman, Susan Murray, MeiLan K Han, Shannon E Cahalan, Blair E Lenhan, Ryan N Best, Jennifer L Taylor-Cousar and 5 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Challenges to assessing the true burden of iron deficiency in cystic fibrosis.Journal of pediatric gastroenterology and nutrition · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Shijing JiaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: sjia@med.umich.edu.
Yizhuo WangDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Melissa H RossDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Jonathan B ZuckermanDepartment of Internal Medicine, Maine Medical Center, Tufts University, Portland, ME, USA.
Susan MurrayDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
MeiLan K HanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Shannon E CahalanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Blair E LenhanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Ryan N BestDepartment of Internal Medicine, Maine Medical Center, Tufts University, Portland, ME, USA.
Jennifer L Taylor-CousarDepartments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO, USA; Departments of Internal Medicine and Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Richard H SimonDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Linda J FitzgeraldDepartment of Pharmacy Services, University of Michigan, Ann Arbor, MI, USA; Sanofi Medical Affairs, Bridgewater, NJ, USA.
Jonathan P TroostMichigan Institute for Clinical Health Research, University of Michigan, Ann Arbor, MI, USA.
Suman L SoodDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Alex H GiffordDepartment of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Pediatrics, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
University of Michigan · USTufts University · USNational Jewish Health · USUniversity Hospitals of Cleveland · USUniversity of Utah · US

Funding

Defining Pathways in COPD Patient Oriented ResearchK24HL138188 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MeiLan K Han · 2017 to 2026
$1.2M
NHLBI NIH HHS K24 HL138188
6 · The paper itself

Abstract

backgroundIron deficiency (ID) is a common extrapulmonary manifestation in cystic fibrosis (CF). CF transmembrane conductance regulator (CFTR) modulator therapies, particularly highly-effective modulator therapy (HEMT), have drastically improved health status in a majority of people with CF. We hypothesize that CFTR modulator use is associated with improved markers of ID.

methodsIn a multicenter retrospective cohort study across 4 United States CF centers 2012-2022, the association between modulator therapies and ID laboratory outcomes was estimated using multivariable linear mixed effects models overall and by key subgroups. Summary statistics describe the prevalence and trends of ID, defined a priori as transferrin saturation (TSAT) <20 % or serum iron <60 μg/dL (<10.7 μmol/L).

resultsA total of 568 patients with 2571 person-years of follow-up were included in analyses. Compared to off modulator therapy, HEMT was associated with +8.4 % TSAT (95 % confidence interval [CI], +6.3-10.6 %; p < 0.0001) and +34.4 μg/dL serum iron (95 % CI, +26.7-42.1 μg/dL; p < 0.0001) overall; +5.4 % TSAT (95 % CI, +2.8-8.0 %; p = 0.0001) and +22.1 μg/dL serum iron (95 % CI, +13.5-30.8 μg/dL; p < 0.0001) in females; and +11.4 % TSAT (95 % CI, +7.9-14.8 %; p < 0.0001) and +46.0 μg/dL serum iron (95 % CI, +33.3-58.8 μg/dL; p < 0.0001) in males. Ferritin was not different in those taking modulator therapy relative to off modulator therapy. Hemoglobin was overall higher with use of modulator therapy. The prevalence of ID was high throughout the study period (32.8 % in those treated with HEMT).

conclusionsID remains a prevalent comorbidity in CF, despite availability of HEMT. Modulator use, particularly of HEMT, is associated with improved markers for ID (TSAT, serum iron) and anemia (hemoglobin).

Indexed as

BiomarkersCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorAdolescentAdultAnemia, Iron-DeficiencyChildChloride Channel AgonistsFemaleHumansIronIron DeficienciesMaleQuinolonesRetrospective StudiesUnited StatesBiomarkersChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorIronQuinolonesAnemiaCFTR modulator therapiesCystic fibrosisIron deficiencyNutrition

Identifiers

PMID38490920
PMCPMC11399321
OpenAlexW4392859395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.